Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 6, 2006

Avicena and NINDS Embark on Phase III Trial for Parkinson's Disease

  • Avicena will supply the National Institute of Neurological Disorders and Stroke (NINDS) with PD-02, the company's lead Parkinson's disease (PD) drug candidate, for a Phase III trial being planned by the Institute. The trial is designed to evaluate PD-02's potential to slow the progression of Parkinson's disease.

    PD-02 has demonstrated the potential to improve neurological function in patients with ALS, Huntington's disease, and Parkinson's disease. The company reports that in preclinical studies, PD-02 showed significant neuroprotective properties, including protection of the dopaminergic cells which are affected in Parkinson's disease.

    As part of its ongoing collaboration with NINDS, Avicena will provide PD- 02 and placebo for the trial and fund a related chronic toxicology study. In turn, Avicena has the right to utilize the study's findings for an NDA submission to the FDA.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »